Kristie Bobolis, MD is a research investigator with the Sutter Roseville Medical Center
Sutter Health Research Enterprise
8 Medical Plaza
Suite 300
Roseville, CA, 95661
(916) 782-5106
bobolik@sutterhealth.org
Related Clinical Trials
Adjuvant (Alliance A011801 Compass HER2 Residual Disease)
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Investigator: Kristie A. Bobolis M.D.
Status: Active, Recruiting
Adjuvant (NRG BN007) Temp Hold
Use of Immunotherapy Ipilimumab and Nivolumab Plus RT Compared to Usual Trmt (Temozolomide and RT) for Newly Dx MGMT Unmethylated Glioblastoma
Investigator: Kristie A. Bobolis M.D.
Status: Active, Not Recruiting
Adjuvant Breast (EndoPredict Extended Endocrine Trial EXET Myriad)
To evaluate the impact of using EndoPredict clinically to inform treatment decisions for extended endocrine therapy and the subsequent impact on patient outcome
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D.
Status: Active, Recruiting
City of Hope 96144 Molecular Genetics Studies of Cancer Patients and Their Relatives
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Metastatic (AstraZeneca D533AC00001 MONETTE)
AstraZeneca D533AC00001 MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresect
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Dron Gauchan MD, Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Status: Active, Recruiting
Neoadjuvant (ECOG-ACRIN EA1181 Compass HER2 pCR)
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Investigator: Kristie A. Bobolis M.D.
Status: Active, Recruiting
The Pathfinder 2 Study (Grail)
Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Investigators: Deepti Behl MD, Kristie A. Bobolis M.D., Alex J. Garica-Young MD, Charles McDonnell MD, FACR, Sivakumar Reddy M.D., Nitin Rohatgi MD
Status: Active, Recruiting
Research Studies
Adjuvant (Guardant Health 02-MX-003 ORACLE)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)
Investigators: Kristin N. Arreola M.D., Deepti Behl MD, Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Jaspreet K Dhillon Medical Oncologist, Brian K. Kim M.D, Sivakumar Reddy M.D., Vijay Suhag M.D.
Dana Farber 13-09-259 DCIS Registry
Molecular Characterization of Breast Cancer with Duct Forming Features
Investigator: Kristie A. Bobolis M.D.
Genomic Health Oncotype DX AR-V7
Genomic Health 09-060
Investigators: Kristin N. Arreola M.D., Kristie A. Bobolis M.D., Rajeswari Chellappah M.D., Brian K. Kim M.D, Sivakumar Reddy M.D., Nitin Rohatgi MD, Vijay Suhag M.D., David S Yee M.D., MPH